Last reviewed · How we verify

NCT06693622

Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests

Recruiting now Last updated 18 November 2024
What this trial tests

trial testing Patient survey in Gastro Esophageal Reflux Disease in 556 participants. Currently enrolling.

Timeline
1 November 2024
Primary endpoint
1 March 2029
1 March 2029

Quick facts

Lead sponsorUniversity of Colorado, Denver
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment556
Start date1 November 2024
Primary completion1 March 2029
Estimated completion1 March 2029
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 18 to 89, any sex, with Gastro Esophageal Reflux Disease or Barrett Esophagus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study plans to learn more about what patients think about screening for esophageal cancer (EAC) and Barrett's esophagus (BE); a pre-cancerous condition associated with esophageal cancer. The plan is to use this information to modify screening practices in the United States with the goal to decrease the number of people who die from esophageal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastro Esophageal Reflux Disease

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06693622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing